Novo CEO pressed by Senate to chop price ranges of obesity, diabetes medications CEO Lars Fruergaard Jørgensen instructed lawmakers the organization would look at new talks with insurers with regards to the listing costs of Wegovy and copyright should they pledge to help keep the medicines on their own formularies. https://kethek.com/